# Cannabinoids: A New Hope for Breast Cancer Therapy? > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-breast-cancer-research/ > **Published:** 2021-09-07T15:36:41-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:16:59-04:00 > **Clinical Summary:** Explore cannabinoids breast cancer research revealing promising antitumor effects and potential integration into breast cancer therapy. --- Breast cancer is one of the most common cancers, affecting approximately 1 in 10 women at some points in their lives. Although the rates of mortality have declined since the late 1990s, certain breast tumors remain resistant to these conventional therapies like chemotherapy and surgery. In addition, many of these treatments have [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) that substantially impair patients’ [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). Therefore, new strategies with low adverse effects continue to be sought after. Experimental evidence accumulated over the last decade supports that cannabinoids such as THC and CBD, the active components of cannabis and their derivatives, possess antitumor activity against a wide range of cancers. They exert such effects through binding to and activating [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), CB1 and CB2, on the surface of cancerous cells. In the case of breast cancer, THC, CBD and their analogs have been found to inhibit proliferation, induce cell death and curb cell migration of different breast cancer cell lines in culture. More encouragingly, studies using mouse models of breast cancer have also proved cannabinoids to hamper tumor growth, angiogenesis (generation of blood vessels that nurture the tumor) and metastasis in animals. In addition, while potent against cancerous cells, cannabinoids are not toxic to non-tumorous cells. Last but not least, cannabinoid-based medicines have been proven very safe in thousands of patients enrolled in multiple [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). For all of these reasons, many scientists are optimistic that medicinal cannabinoids can be incorporated into current standard treatment regimens for breast cancer to improve patients outcomes. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Urgent need for clinical trials investigating the effects of cannabinoids on hormone receptor-positive breast cancer therapy](https://cedclinic.com/cannabinoids-hormone-receptor-positive-breast-cancer/) This article highlights the critical need for [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to evaluate cannabinoids' effects on hormone receptor-positive breast cancer, emphasizing research gaps and future directions. [Read More](https://cedclinic.com/cannabinoids-hormone-receptor-positive-breast-cancer/) [Cannabidiol Drug Interactions: Clinical Evidence for Safe Use](https://cedclinic.com/cannabinoid-drug-interactions-clinical-evidence/) Review clinical evidence on cannabidiol's [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/) to understand its safety profile and implications for patients undergoing complex treatments. [Learn More](https://cedclinic.com/cannabinoid-drug-interactions-clinical-evidence/) [Cannabinoid Pain Relief: Sodium Channel Modulation Research](https://cedclinic.com/cannabinoid-pain-relief-sodium-channel-modulation-research/) Explore research on cannabinoids' role in pain relief through sodium channel modulation, relevant for managing cancer-related symptoms. [Discover Insights](https://cedclinic.com/cannabinoid-pain-relief-sodium-channel-modulation-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoids%3A%20A%20New%20Hope%20for%20Breast%20Cancer%20Therapy%3F&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-breast-cancer-research%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-breast-cancer-research%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoids%3A%20A%20New%20Hope%20for%20Breast%20Cancer%20Therapy%3F%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-breast-cancer-research%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).